AbbVie reports that its investigational drug etentamig produced a 74% response rate in relapsed multiple myeloma, against 45.7% for standard therapies.
An Experimental Myeloma Drug Given Monthly Outperformed Standard Options in Patients Who Exhausted Three Treatment Classes
by | Sep 5, 2026 | Uncategorized | 0 comments
Recent Comments